Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$7,599 Mln
Revenue (TTM)
$88 Mln
Net Profit (TTM)
$0 Mln
ROE
-5.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
60.3
Industry P/E
--
EV/EBITDA
-15.8
Div. Yield
0 %
Debt to Equity
-1.9
Book Value
$--
EPS
$-6.4
Face value
--
Shares outstanding
123,162,807
CFO
$-1,144.29 Mln
EBITDA
$-1,391.98 Mln
Net Profit
$-1,754.13 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cytokinetics Inc (CYTK)
| -1.6 | -0.2 | -1.0 | 43.3 | 23.3 | 21.2 | 25.1 |
|
BSE Sensex
| -13.1 | -10.5 | -13.5 | -4.8 | 8.6 | 8.5 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Cytokinetics Inc (CYTK)
| 35.1 | -43.4 | 82.2 | 0.5 | 119.3 | 95.9 | 67.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cytokinetics Inc (CYTK)
|
62.5 | 7,599.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 |
| 57.8 | 7,888.0 | 1,091.0 | 202.3 | 31.6 | 31.3 | 35.2 | 13.9 | |
| 217.0 | 13,621.9 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 41.5 | 11,065.0 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.8 | 5.0 | |
| 84.6 | 11,173.1 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 61.6 | 7,485.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.7 | 153.4 | |
| 7.4 | 8,708.1 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 510.7 | 10,120.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 451.2 | 12,842.8 | 2,530.2 | 451.1 | 21.3 | 70.2 | 29.6 | 28.5 | |
| 290.1 | 8,308.2 | 0.0 | -303.3 | -- | -45.8 | -- | 9.5 |
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets... MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California. Read more
CEO, President, Principal Financial Officer & Director
Mr. Robert I. Blum
CEO, President, Principal Financial Officer & Director
Mr. Robert I. Blum
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Cytokinetics Inc (CYTK) is $62.50 (NASDAQ) as of 27-Mar-2026 16:09 EDT. Cytokinetics Inc (CYTK) has given a return of 23.28% in the last 3 years.
Since, TTM earnings of Cytokinetics Inc (CYTK) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-9.91
|
-11.79
|
|
2024
|
-9.42
|
-41.03
|
|
2023
|
-15.72
|
-21.41
|
|
2022
|
-11.15
|
-40.21
|
|
2021
|
-17.80
|
15.72
|
The 52-week high and low of Cytokinetics Inc (CYTK) are Rs 70.98 and Rs 29.31 as of 28-Mar-2026.
Cytokinetics Inc (CYTK) has a market capitalisation of $ 7,599 Mln as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Cytokinetics Inc (CYTK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.98
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.